How to Place a Medical Device on the Singapore Market in 2026: SMDR versus Class A Notification versus Dealer Licence versus Registrant, GN-15 R13 Evaluation Routes and Malaysia MDA Reliance, Official Fees as of 26 March 2026, and Why CE / 510(k) / NMPA Do Not Replace an HSA Listing

Target Audience & Operational Scope: This regulatory guide is designed for international medical device manufacturers, Singapore-based distributors, OEM/ODM private-label buyers, and hospital procurement teams evaluating or placing sterile single-use surgical, vascular, and perioperative devices on the Singapore market in 2026. It establishes the exact legal boundaries between the Singapore Medical Device Register (SMDR), Class A SHARE product notifications, Singapore Registrant appointments, dealer licensing (importer, wholesaler, manufacturer), GN-15 Revision 13 evaluation routes, Malaysia Medical Device Authority (MDA) regulatory reliance, and the live 26 March 2026 Health Sciences Authority (HSA) fee structure.

Table of Contents:

• 1. Does a CE Mark, 510(k), NMPA Certificate or MDSAP Certificate Replace Singapore SMDR Listing or Class A Notification?
• 2. Who Is the Registrant, Who Holds the Dealer Licences, and Why Those Roles Are Not Interchangeable?
• 3. When Is Class A Notification Enough, and Why Sterile Class A Still Is Not SMDR Product Registration?
• 4. Which Overseas Approvals Open GN-15 R13 Abridged, Expedited or Immediate Class B Routes, and Why NMPA and UKCA Do Not?
• 5. Can a Malaysia MDA Listing Open Immediate Class B Registration, or Only Abridged Evaluation?
• 6. What Immediate Class B Actually Does: Listing upon Payment, Later Verification, Cancellation Without Refund
• 7. What the Official 26 March 2026 Fee Card and Working-Day Clocks Print, Including Dealer Licences and SMDR Retention
• 8. SHARE versus MEDICS: Which Portal Accepts New Submissions After 14 July 2025?
• 9. What a Public SMDR Row Can and Cannot Prove, versus the Unverified Class A Database
• 10. Worked Examples: A CE-Marked Circumcision Ring versus an NMPA-Only Laser Fiber, and a Class I Aftercare SKU
• 11. Distributor Checklist, Agreement Terms, and Red Flags Before the First Singapore Shipment
• 12. Where VEMERIX Fits—and Where Due Diligence Still Begins
• 13. Frequently Asked Questions (FAQ)

Does a CE Mark, 510(k), NMPA Certificate or MDSAP Certificate Replace Singapore SMDR Listing or Class A Notification?

In international medical device distribution, commercial teams frequently encounter the misconception that holding an internationally recognised certification—such as an EU CE mark under Regulation (EU) 2017/745 (MDR), a US FDA 510(k) clearance, a China National Medical Products Administration (NMPA) medical device registration certificate, or a Medical Device Single Audit Program (MDSAP) certificate—allows a manufacturer to ship goods directly into Singapore. In regulatory law, this premise is false ^{1 9}.

Under the Health Products Act 2007 (2020 Revised Edition) and the Health Products (Medical Devices) Regulations 2010, Singapore enforces territorial control over medical-device market access ^{9 10}. Placing a medical device on the Singapore market requires two distinct legal instruments:

1. Product authorisation: Class B, Class C and Class D devices must be registered (Health Products Act s 30) before they can be supplied, because s 15 prohibits supply of an unregistered health product except as prescribed. Class A devices are excepted from that prohibition by regulation 10B where the device is manufactured, imported or obtained from a licensed dealer; manufacturers and importers still submit a Product Notification in SHARE under GN-22 and GN-15, and regulation 12 requires the supplier to furnish information HSA requires ^{1 10}.
2. Establishment authorisation: Manufacture, import and wholesale are separate licensed activities: manufacturer's licence (s 12), importer's licence (s 13) and wholesaler's licence (s 14), issued under Part 6. HSA's dealer-licence page states that licensed importers require a wholesaler's licence for wholesale supply, while licensed manufacturers do not need a wholesaler's licence to supply devices they manufacture ^{1 4 9}.

Overseas regulatory approvals from recognised reference agencies do not substitute for an HSA listing. Instead, under HSA guidance document GN-15 Revision 13 (March 2026), foreign approvals serve exclusively as technical and clinical evidence to qualify a submission for accelerated evaluation pathways—namely the Abridged, Expedited, or Immediate Class B routes ⁵. Without an active SMDR registration number or a valid Class A Product Notification receipt issued by HSA, physical customs clearance and commercial supply in Singapore constitute statutory offences under the Health Products Act ⁹.

Who Is the Registrant, Who Holds the Dealer Licences, and Why Those Roles Are Not Interchangeable?

A primary area of structural confusion for international device exporters is the division of responsibility between the Registrant and the Dealer. In Singapore's legal architecture, these are two completely distinct regulatory identities governed by separate statutory provisions ^{1 4 9}.

Under Section 2 of the Health Products Act 2007, the Registrant, in relation to a registered health product, is "the person who applied for and obtained the registration of the health product under this Act" ⁹. Operationally, SHARE is accessed with Corppass, so the applicant is a Singapore entity that can log in; the foreign Product Owner is not the typical SMDR holder. The Product Owner executes a Letter of Authorisation using the GN-15 Revision 13 Annex 1 template, granting the local entity authority to submit and maintain the listing ^{5 8}. The Registrant remains accountable for post-market duties in Part VIII of the Regulations, including reporting of defects and adverse effects under regulation 42 and recall notification under regulation 44 ¹⁰. Compare who is the Product Owner before you appoint a Singapore Registrant.

Conversely, a Dealer Licence governs commercial and physical handling activities ⁴. Under HSA's dealer-licence page there are three licence types:

• Manufacturer's Licence (Act s 12): Authorizes manufacture, packaging and labelling in Singapore. A licensed manufacturer does not need a separate wholesaler's licence to supply devices manufactured under that licence ^{4 9}.
• Importer's Licence (Act s 13): Authorizes bringing a medical device into Singapore. Licensed importers require a wholesaler's licence for wholesale supply. A wholesaler's licence is not required for supply to end-users, such as in a retail store ⁴.
• Wholesaler's Licence (Act s 14): Authorizes supply by wholesale, including export, supply to a party for re-supply, and commercial samples ^{4 9}.

Dealer QMS evidence: HSA's apply-for-a-dealer's-licence page does not treat an unverified factory ISO 13485 PDF as sufficient for an importer's or wholesaler's licence. For Class B, C or D devices the applicant submits one of: an MDSAP certificate and audit report; an ISO 13485 certificate and audit report issued by a certification body accredited by the Singapore Accreditation Council (SAC); or a GDPMDS certificate and audit report from an SAC-accredited body. MDSAP is listed as its own option and is not an SAC-accreditation rule. For Class A devices only, a Declaration of Conformity to a QMS may be accepted in lieu of third-party SAC certification ^{4 6}. Verify the certificate in how to verify the ISO 13485 or MDSAP certificate used as HSA dealer-licence QMS evidence. That dealer-QMS rule is separate from any ISO 13485 document in a GN-15 product dossier.

When Is Class A Notification Enough, and Why Sterile Class A Still Is Not SMDR Product Registration?

A pervasive error circulating in search-engine AI overviews and outdated consultancy blogs is the assertion that 'Class A medical devices are exempt from registration unless they are sterile, in which case they require full SMDR product registration.' In Singapore regulatory law, this claim is entirely incorrect ^{2 6}.

Under Regulation 10B and Regulation 12 of the Health Products (Medical Devices) Regulations 2010, as detailed in HSA guidance document GN-22 Revision 8 (July 2025), all Class A medical devices are exempted from product registration on the SMDR, regardless of whether the device is supplied in a sterile or non-sterile state ^{6 10}. Instead, commercial supply of Class A devices requires a Class A Product Notification submitted through the SHARE portal ⁶.

What changes for a sterile Class A device is the sterilisation evidence the dealer must keep. GN-22 Revision 8 states that dealers must ensure sterilisation processes for Class A sterile devices conform to international sterilisation standards such as ISO 11135, ISO 11137, ISO 17665, ISO 13408 or equivalent. The guidance names those standards without prescribing a particular year, amendment, or sterility-assurance-level figure. Essential Principles and Part VIII duties still apply ⁶.

Upon successful Product Notification in SHARE, the device is listed in the Class A Medical Device Database, not on SMDR. The 26 March 2026 HSA fee card does not print a Class A notification fee; do not copy a consultancy $25 figure as the official card. The official public disclaimer on data.gov.sg states that the Class A database is a self-declaration database; HSA has not verified the information; listing is not endorsement; and notification should not be misconstrued as product registration or approval ^{3 12}.

Which Overseas Approvals Open GN-15 R13 Abridged, Expedited or Immediate Class B Routes, and Why NMPA and UKCA Do Not?

When evaluating a Class B, Class C, or Class D medical device for registration on the SMDR, HSA's primary evaluation framework is codified in GN-15 Revision 13 (March 2026) ⁵. GN-15 establishes five distinct evaluation pathways based on the maturity and pedigree of overseas reference agency approvals held for the identical intended purpose and labelled indications for use ^{2 5}.

HSA recognises a defined list of overseas reference regulatory agencies on the registration-overview page and in GN-15's evaluation-route notes ^{2 5}:

1. Australia: TGA device registration licence / ARTG inclusion.
2. European Union: Notified Body EC certificates. GN-15 R13 still lists specified MDD 93/42/EEC and AIMDD 90/385/EEC annexes alongside MDR Annex IX/X/XI for the matching Singapore class — that is the printed certificate list, not a claim that every MDD certificate remains valid in the EU.
3. Canada: Health Canada Medical Device Licence (MDL) for Class II, III or IV.
4. Japan: MHLW Shonin or Ninsho.
5. United States: FDA 510(k), De Novo or PMA.

The Class I / Class II-exempt exclusion: GN-15's evaluation-route notes, and the HSA registration-overview table, state that Class B, C and D medical devices classified and approved or cleared as Class I or Class II exempt at the listed reference agencies do not qualify for abridged, expedited or immediate routes on those approvals ^{2 5}. The file then follows the full evaluation route. Singapore class is assigned under regulation 24 and HSA's current classification guidance, not by copying an archived GN-13 rule number ^{10 14}.

Why NMPA, UKCA, and MFDS do not open those routes: NMPA, MHRA/UKCA and MFDS are not listed as HSA reference agencies on the registration-overview table or in GN-15's GHTF founding-member set ^{2 5}. A UKCA certificate therefore does not open abridged or Immediate Class B; see why a UKCA certificate does not open a Singapore abridged or Immediate Class B route. An SFDA MDMA is likewise KSA-only; see why an SFDA MDMA does not place the same device in Singapore. A device holding only an NMPA certificate follows the full evaluation route unless it also holds a listed reference-agency approval for the same labelled use or qualifies under Section 6 Malaysia reliance ^{3 5}. Verify a CE certificate before treating it as abridged evidence in how to verify a CE certificate before you treat it as Singapore abridged-route evidence, and a 510(k) in how to verify a 510(k) used as Singapore reference-agency evidence rather than as an HSA listing.

Can a Malaysia MDA Listing Open Immediate Class B Registration, or Only Abridged Evaluation?

A key regional development in ASEAN medical device harmonization is HSA's regulatory reliance framework with Malaysia's Medical Device Authority (MDA), formalised under GN-15 Revision 13 Section 6.1 ⁵. However, distributors frequently misunderstand the exact scope of this reliance.

Under GN-15 Section 6.1, HSA permits a Singapore Registrant to leverage a medical device registration issued by the Malaysia Medical Device Authority under Act 737 to access the Abridged Evaluation Route in Singapore, subject to three strict prerequisite conditions:

1. The medical device must be registered with the Malaysia MDA.
2. The Malaysia registration must have been evaluated and certified by an MDA-registered Conformity Assessment Body (CAB) through full conformity assessment (not via abridged or verification routes).
3. The device must have the identical intended purpose, indications for use, and design configuration as registered in Malaysia ⁵.

Malaysia MDA does not open Immediate Class B Registration: GN-15 Section 6.1 is an abridged-only reliance programme. Immediate Class B still needs independent reference-agency approvals under the IBR conditions. A Malaysia-registered Class B device without those approvals follows abridged evaluation (100 working days and $2,010 evaluation fee on the 26 March 2026 card) ^{2 3 5}. Section 6.1 also excludes medical devices incorporating registrable therapeutic/medicinal products and borderline products classified differently by MDA and HSA. This is Singapore reliance on a Malaysia file, not a Malaysia market-entry guide.

What Immediate Class B Actually Does: Listing upon Payment, Later Verification, Cancellation Without Refund

The Immediate Class B Registration Route is one of the most attractive—yet commercially risky—market-entry mechanisms offered by HSA ^{2 5}. Under GN-15 Revision 13 Annex 4, an eligible Class B medical device is registered and listed on the SMDR immediately upon successful electronic submission and confirmation of fee payment ($560 application fee + $1,000 evaluation fee) ^{3 5}.

To qualify for Immediate Class B Registration, GN-15 states that a Class B device must fulfil one of two conditions at the point of submission:

• Condition 1: approval from at least one of HSA's independent reference regulatory agencies for an identical labelled use, marketed for at least three years in that jurisdiction, no safety issues globally, and no prior rejection or withdrawal by HSA or those agencies ^{2 5}.
• Condition 2: approval from at least two independent reference regulatory agencies, with no safety issues globally and no prior rejection or withdrawal — not a marketing-duration-free shortcut that drops the safety declaration ^{2 5}.

Post-listing verification and cancellation without refund: Immediate listing is not 'no review'. GN-15 section 4.3.1 states that for immediate routes the device is listed on SMDR upon successful submission and receipt of full payment; online payment processes immediately, while GIRO takes 3 to 5 working days. Applicants must fulfil all eligibility criteria. Any IBR application that fails those criteria, or a non-Class B device submitted via IBR, results in cancellation of the registration and fees will not be refunded. HSA will verify the documents submitted after successful submission ⁵. GN-15 does not print a '100% of CSDT dossiers' audit statistic; the printed rule is post-submission verification plus cancellation without refund for ineligible filings.

If HSA finds the device ineligible—including a Class C or Class D device filed via Immediate Class B—GN-15 states that the registration is cancelled and fees are not refunded. Application fees are non-refundable once submitted; evaluation fees are non-refundable once the application is accepted for evaluation. Stock already imported against a cancelled listing is unregistered for s 15 purposes unless another printed exception applies ^{3 5 9}.

What the Official 26 March 2026 Fee Card and Working-Day Clocks Print, Including Dealer Licences and SMDR Retention

Commercial forecasting requires current statutory fee schedules. Many third-party consultancy websites still display outdated pre-2024 fee tables. As published on the official HSA fee schedule (last updated 26 March 2026), all fees are denominated in Singapore dollars (SGD) and are legally non-refundable once an application is initiated ³.

*Immediate Class C on the fee card: The official card lists an Immediate Class C evaluation fee of $3,340. HSA's registration overview limits that immediate pathway to standalone medical mobile applications. Physical surgical instruments, sterile consumables, vascular laser fibers, or implantable Class C devices cannot use it and must follow expedited, abridged or full evaluation ^{2 3}. Class A product notification is not printed as a fee line on the 26 March 2026 card.

Applicant stop-clock: Official HSA turnaround times are working-day clocks and exclude the time taken for the applicant to respond to requests for clarification or additional information ³. GN-15 states that the stop-clock begins when HSA issues an input request and ends only upon receipt of a complete and satisfactory response. If the device is the subject of an FSCA, the application is placed on stop-clock until resolution. Those clocks are service-standard prints, not guaranteed calendars. This article does not invent a 30-day terminate-and-forfeit rule that is not on the fee card or in the extracted GN-15 processing notes ^{3 5}.

SHARE versus MEDICS: Which Portal Accepts New Submissions After 14 July 2025?

In search engine results, multiple ranking consultancy articles (such as Qserve's May 2023 overview) continue to instruct foreign manufacturers to file medical device dossiers in the Medical Device Information and Communication System (MEDICS) ⁷. This advice is completely obsolete.

On 23 June 2025, HSA announced SHARE — the Singapore Health Product Access and Regulatory E-System — as the replacement for MEDICS for medical-device product registration and licence submissions ^{7 8}:

• From 27 June 2025, HSA stopped accepting new application submissions via MEDICS. Input-request responses for ongoing MEDICS applications were still accepted until cut-over ⁷.
• On 14 July 2025, SHARE went live for new medical-device e-services. Companies access it with Corppass ^{7 8}.
• The announcement's cut-over table also records a 4–13 July 2025 MEDICS take-down window. Treat that as the published migration schedule, not a second legal duty ⁷.

Foreign manufacturers auditing Singapore distributors must verify that the distributor's regulatory staff are fully onboarded to SHARE via Corppass. Any distributor agreement, regulatory strategy document, or standard operating procedure referencing MEDICS submission workflows is an immediate red flag indicating outdated regulatory processes ⁷.

What a Public SMDR Row Can and Cannot Prove, versus the Unverified Class A Database

Distributors, hospital procurement committees, and OEM buyers frequently perform due diligence by searching public databases on data.gov.sg or the public SMDR search on SHARE ^{11 15}. Understanding the structural boundaries of these public registers is vital for compliance.

SMDR directory snapshot (labelled public-search limitation): Independently recomputed from the official HSA Listing of Registered Medical Devices (April 2026 grain, last updated 8 June 2026; snapshot date 1 September 2026), that public extract contains 20,860 registered-device rows ¹¹. Those rows are directory facts, not a verified legal census of every authorised shipment and not incidence. The ready extract resolves to 3,791 product-owner entities; the jsonl has 4,383 raw product-owner name strings and 870 raw Singapore registrant name strings ¹¹. For how a public SMDR identity search differs from authorisation to place a fiber on the market, see how public SMDR identity for a laser fiber differs from authorisation to place that fiber on the Singapore market.

The risk class breakdown of the SMDR confirms the legal structure of Singapore registration:

• Class B (Moderate Risk): 11,968 listings (57.4% of the total register).
• Class C (Moderate-High Risk): 6,296 listings (30.2%).
• Class D (High Risk): 2,401 listings (11.5%).
• Class D with Medicinal Product: 195 listings (0.9%).
• Class A (Low Risk): Exactly 0 listings on SMDR, confirming that Class A devices are completely excluded from the SMDR and reside solely in the Class A notification database ^{11 12}.

Crucial Due Diligence Limitations:

1. An SMDR Row Is Unique to Its Named Registrant: A public listing on SMDR proves only that the specific Singapore company named as the Registrant holds authorization to supply that device. If Distributor A holds an SMDR listing for Brand X, Distributor B cannot import Brand X under Distributor A's SMDR number. Distributor B must either be authorized by Distributor A under a secondary dealer agreement or obtain its own SMDR listing with a separate Letter of Authorisation from the Product Owner ^{5 9}.
2. A Search Miss Does Not Equal Non-Registration: Searching a trade name on SMDR may yield zero hits if the device was registered under an overarching system name, GMDN term, or family licence (e.g., 'Diode Surgical Laser System' rather than a specific fiber model). The authoritative proof of registration is the official HSA-issued Registration Certificate held in the Registrant's SHARE account ⁸.
3. Disambiguation of Similar Corporate Names: A search for 'Medison' on the public SMDR reveals 30 rows belonging to Samsung Medison Co., Ltd. (diagnostic ultrasound systems) ¹¹. These are entirely separate legal entities from Weihai Medison Medical Equipment Co., Ltd. (the manufacturer of VEMERIX urology and vascular surgical devices). Similarly, Weihai-based listings on SMDR include Foosin Medical Supplies / WEGO sutures (registered by Topmed Pte Ltd) and Shandong Weigao blood purification lines (registered by Arqon Pte Ltd) ¹¹. Due diligence requires matching the exact Product Owner legal name and manufacturing facility address.

Worked Examples: A CE-Marked Circumcision Ring versus an NMPA-Only Laser Fiber, and a Class I Aftercare SKU

To see how the two-pillar framework applies to a foreign manufacturer's file, consider three representative case studies. These are filing-path contrasts, not classification certificates: the manufacturer classifies under regulation 24 and HSA's current classification guidance. This article does not assign a Singapore class or SMDR number to a named VEMERIX SKU ^{5 14 16 17}:

Case Study 1: Circumcision Device (self-detaching ring) — CE-marked and NMPA-registered
The public VEMERIX Circumcision Device page records an NMPA Class II registration in China, a CE mark, and EO sterilisation ¹⁶.

• Singapore classification: Not assigned in this article. NMPA Class II and any EU class analogue are not Singapore class. In the public SMDR extract, related circumcision-device names (PlastiBell, Touchstone stapler, ZSR anastomat, ShangRing) appear as Class B directory rows — proof a related family is listable, not proof VEMERIX is listed, and not a ranking ^{11 14}.
• Evaluation pathway: If the manufacturer classifies the device as Class B, C or D, a CE certificate can support abridged or Immediate Class B only if the EU Notified Body annex matches the Singapore class HSA will evaluate and the labelled use is identical. Immediate Class B still needs the GN-15 IBR conditions, including the safety declaration. CE does not allow shipment by itself ^{3 5}.
• Commercial gate: The Singapore importer still needs the dealer licences that match import and wholesale, with MDSAP or SAC-accredited ISO 13485/GDPMDS as printed on the dealer-licence page ⁴.

Case Study 2: Disposable Medical Laser Fiber (1470 nm endovenous) — NMPA-registered only
The public Disposable Medical Laser Fiber page records NMPA Class II (Lu Mech Reg. 20192010517) for 1470 nm endovenous workflows with a partner-supplied diode laser source. Medison does not hold a CE mark for this fiber SKU. The partner-supplied NOVACURE console's CE flag is not a Medison CE claim for the fiber ¹⁷.

• Singapore classification: Not assigned in this article. An energy-delivery vascular fiber can engage higher HSA classification rules than NMPA Class II. That is a classification exercise, not a published VEMERIX Singapore class ¹⁴.
• Evaluation pathway: NMPA is not an HSA reference agency, so NMPA alone does not open abridged or Immediate Class B. The default is full evaluation unless a listed reference-agency approval or a GN-15 Section 6 Malaysia full-CAB registration exists for the same labelled use ^{3 5}. Country-of-origin evidence is verified in how to verify the China NMPA certificate used as country-of-origin evidence.
• Commercial gate: Neither the partner console CE certificate nor an NMPA export certificate places the fiber on the Singapore market ^{1 5}.

Case Study 3: Post-operative protective garment / aftercare dressing
Consider a non-invasive post-operative wound-protection garment (for example Circum-CARE pants) or a simple wound pad ¹⁶.

• Singapore classification: Not assigned in this article. Do not copy an overseas NMPA Class I recordation into Singapore. If the manufacturer classifies a non-invasive physical barrier as Class A under regulation 24, the placement instrument is Class A Product Notification in SHARE, not SMDR. If the product incorporates active wound-healing compounds or antimicrobial claims, HSA classification can land higher ¹⁴.
• Evaluation pathway: If Class A, the licensed manufacturer or importer files a Product Notification in SHARE. No SMDR dossier and no Class B/C/D evaluation fee. If the SKU is supplied sterile, GN-22 still requires sterilisation-standard evidence such as ISO 11135, ISO 11137, ISO 17665 or ISO 13408 or equivalent ^{6 8}.

Distributor Checklist, Agreement Terms, and Red Flags Before the First Singapore Shipment

Before releasing commercial shipments of sterile surgical or vascular consumables to Singapore, international manufacturers and local distributors should execute a rigorous eight-point compliance check ^{1 4 5 13}:

1. Verify Singapore risk classification: Confirm the product class under HSA's current classification guidance and regulation 24. Do not assume an EU Class IIa or NMPA Class II SKU is automatically Singapore Class B.
2. Validate Product Authorization Status: For Class B, C, or D devices, verify the active SMDR listing certificate in the Registrant's SHARE account. For Class A devices, verify the Class A Product Notification acknowledgement receipt.
3. Audit Importer & Wholesaler Dealer Licences: Confirm that the Singapore entity clearing customs holds an active Importer's Dealer Licence, and that the entity distributing to hospitals holds an active Wholesaler's Dealer Licence.
4. Verify SAC-Accredited QMS / GDPMDS: Inspect the distributor's ISO 13485 or GDPMDS certificate to confirm it was issued by a certification body accredited by the Singapore Accreditation Council (SAC) and that its scope covers the specific device categories and temperature/humidity storage conditions.
5. Execute GN-15 Annex 1 Letter of Authorisation: Ensure the Product Owner executes the standard HSA Letter of Authorisation specifically naming the Singapore Registrant and defining the exact device models covered.
6. Incorporate Registration Transfer Clauses (GN-24): In the commercial distributor agreement, include explicit covenants governing change of registrant under GN-24 R2 ($880 fee / 40 working days). If the commercial distribution agreement terminates, the local distributor must be contractually obligated to execute the HSA Relinquishing Company Form and transfer the SMDR listing to the Product Owner or its newly appointed designee.
7. Establish vigilance and recall SOPs: Regulation 42 requires reporting of defects and adverse effects within 48 hours for a serious public-health threat, 10 days for death or serious deterioration in health, and 30 days for an event whose recurrence might lead to death or serious deterioration. Regulation 44 requires notification at least 24 hours before an intended recall.
8. Audit Packaging & Labelling Conformity: Verify that primary and secondary packaging carry required Singapore labelling (including Singapore Registrant contact details where required, sterile barrier symbols conforming to ISO 15223-1, lot numbers, expiry dates, and English IFU).

Where VEMERIX Fits—and Where Due Diligence Still Begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care ¹⁶.

In Singapore market-access discussions, VEMERIX can support a current technical pack rather than a claimed listing:

• Urology surgical portfolio: For the CE-marked Circumcision Device (self-detaching ring), Medison can discuss CSDT-structured technical files, ISO 13485 QMS evidence, EO sterilisation validation, and a Product Owner Letter of Authorisation (GN-15 Annex 1) for a Singapore Registrant to file under the route the manufacturer's Singapore class and reference-agency evidence actually support. CE does not replace SMDR ^{5 16}.
• Vascular laser consumables: For the NMPA-registered Disposable Medical Laser Fiber (1470 nm), Medison can discuss country-of-origin registration, manufacturing records, and a letter of authorisation for a Full Evaluation CSDT if that is the route the manufacturer's Singapore class requires. The partner-supplied diode laser source is not a Medison-manufactured or Medison-registered capital system ¹⁷.

Where due diligence begins: VEMERIX does not sell pre-packaged SMDR registration numbers or local dealer licences. Legal market placement in Singapore begins with the buyer appointing a qualified Singapore Registrant, putting the matching dealer licences and QMS evidence in place, and verifying the listing in SHARE. Request the current technical dossier, letter of authorisation and dealer-QMS pack via VEMERIX Contact and review manufacturing standards on the VEMERIX Quality portal. If a buyer is asked for an export certificate, verify it in how to verify a Certificate of Free Sale used in a Singapore-bound or Singapore-issued file ¹⁶.

Frequently Asked Questions (FAQ)

Do I still need an HSA SMDR listing if my device already has a CE mark, FDA 510(k), or China NMPA certificate?

Yes. An overseas CE mark, FDA 510(k), or China NMPA certificate does not authorize commercial supply in Singapore. Under the Health Products Act 2007, Class B, C, and D devices must be registered on the Singapore Medical Device Register (SMDR), and Class A devices must be notified via SHARE. Overseas approvals serve only as technical evidence to access accelerated GN-15 evaluation routes.

Does a sterile Class A medical device require SMDR product registration?

No. Under Regulation 10B of the Health Products (Medical Devices) Regulations 2010 and GN-22 Revision 8, all Class A devices—sterile or non-sterile—are exempted from SMDR registration. They require a Class A Product Notification in SHARE and are listed in the Class A Medical Device Database. For sterile Class A devices, the dealer must maintain validation proof conforming to ISO 11135, ISO 11137, ISO 17665, or ISO 13408.

Is the Singapore Registrant the same legal entity as the importer holding a dealer licence?

Not necessarily. The Registrant is the local Singapore entity holding the Product Owner's Letter of Authorisation who applies for and maintains the SMDR listing. The Importer is the entity holding an Importer's Dealer Licence authorizing physical importation. A single Singapore company can hold both roles, but they are governed by separate statutory licences and require separate QMS authorizations.

Does a Malaysia MDA certificate qualify for Immediate Class B Registration in Singapore?

No. Under GN-15 Revision 13 Section 6.1, a Malaysia MDA registration via an MDA-recognised Conformity Assessment Body (CAB) qualifies exclusively for the Abridged Evaluation Route (100 working days / $2,010 fee). Immediate Class B Registration strictly requires independent pre-market approvals from founding reference agencies (US FDA, EU Notified Body, Health Canada, TGA, or Japan MHLW).

How much are official HSA product registration and dealer licence fees as of 26 March 2026?

As of the official 26 March 2026 fee schedule, Class B/C/D applications require a $560 application fee. Evaluation fees are: Class B Immediate $1,000, Class B Abridged $2,010, Class B Full $3,900; Class C Abridged $3,900, Class C Full $6,250; Class D Abridged $6,250, Class D Full $12,000. Annual SMDR retention fees are $39 (Class B), $67 (Class C), and $134 (Class D). Dealer licences cost $1,110 per licence type (Manufacturer, Importer, Wholesaler) with $168 amendment fees. All fees are in Singapore dollars (SGD).

Does another company's SMDR listing cover my shipment of the same device model?

No. An SMDR listing is legally unique to the specific Singapore Registrant named on the register. Another distributor cannot import or supply goods against that listing without formal secondary authorization from the Registrant or obtaining its own separate SMDR registration supported by a Letter of Authorisation from the Product Owner.

Should new Singapore medical device applications still be submitted in MEDICS?

No. HSA stopped accepting new MEDICS submissions on 27 June 2025. On 14 July 2025, SHARE (Singapore Health Product Access and Regulatory E-System) became the live portal for new medical-device registrations, Class A notifications and dealer licences. Companies access SHARE with Corppass.

Does VEMERIX already hold an SMDR listing or HSA dealer licence for these SKUs?

Weihai Medison Medical Equipment Co., Ltd. (VEMERIX) is a medical device manufacturer. Product listings on the SMDR and dealer licences in Singapore are held by licensed local Singapore Registrants and distributors. Medison provides complete CSDT dossiers, sterilization validation reports, and Letters of Authorisation to support appointed Singapore partners.